Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Narikazu Boku

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1438-707X; OpenAlex author ID A5010090426, A5071411436, A5077365053. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
109
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 3 papers

Papers 21

  1. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Co-author DOI 10.1002/jhbp.70117↗
  2. Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovori… Co-author DOI 10.1007/s00520-026-10845-1↗
  3. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  4. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Last author DOI 10.21873/anticanres.16601↗
  5. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Syst… Co-author DOI 10.1001/jamaoncol.2022.0168↗
  6. Concordance of human equilibrative nucleoside transporter-1 expressions between murine (10D7G2) and rabbit (SP120) antibodies and association with clinical out… First author DOI 10.1002/cnr2.1507↗
  7. Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy. Co-author DOI 10.1111/cas.14258↗
  8. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  9. Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (… Co-author DOI 10.1016/j.ejca.2018.01.081↗
  10. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  11. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  12. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  13. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). First author DOI 10.1016/s0140-6736(16)30583-9↗
  14. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Last author DOI 10.1093/annonc/mdv603↗
  15. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global ra… Co-author DOI 10.1093/jjco/hyv011↗
  16. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  17. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer? Last author DOI 10.1111/cas.12709↗
  18. Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Last author DOI 10.1111/cas.12501↗
  19. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  20. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyr090↗
  21. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Co-author DOI 10.1111/j.1349-7006.2010.01810.x↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Akira Fukutomi · 12 shared papers, 2013–2026 · strength 1.09
  2. Katsuhiko Uesaka · 6 shared papers, 2016–2026 · strength 0.82
  3. Hirochika Toyama · 4 shared papers, 2020–2026 · strength 0.72
  4. Shoji Nakamori · 10 shared papers, 2011–2022 · strength 0.58
  5. Yukiyasu Okamura · 5 shared papers, 2016–2026 · strength 0.53
  6. Soichiro Morinaga · 5 shared papers, 2016–2026 · strength 0.53
  7. Naoto Gotohda · 2 shared papers, 2026 · strength 0.52
  8. Kazunaga Ishigaki · 2 shared papers, 2026 · strength 0.51
  9. Mitsuhiro Fujishiro · 2 shared papers, 2026 · strength 0.51
  10. Takuji Okusaka · 11 shared papers, 2011–2019 · strength 0.47
  11. Junji Furuse · 10 shared papers, 2011–2019 · strength 0.43
  12. Amane Takahashi · 3 shared papers, 2020–2026 · strength 0.43
  13. Tatsuya Ioka · 9 shared papers, 2011–2019 · strength 0.41
  14. Nobumasa Mizuno · 5 shared papers, 2015–2023 · strength 0.36
  15. Shinichi Ohkawa · 9 shared papers, 2011–2017 · strength 0.36
  16. Atsuyuki Maeda · 2 shared papers, 2022–2026 · strength 0.34
  17. Naohiro Sata · 4 shared papers, 2016–2022 · strength 0.30
  18. Dongha Lee · 1 shared paper, 2026 · strength 0.29
  19. Jun Ishida · 1 shared paper, 2026 · strength 0.29
  20. Takuya Mizumoto · 1 shared paper, 2026 · strength 0.29
  21. Yoshihide Nanno · 1 shared paper, 2026 · strength 0.29
  22. Yurie Tokito · 1 shared paper, 2026 · strength 0.28
  23. Naminatsu Takahara · 1 shared paper, 2026 · strength 0.28
  24. Go Endo · 1 shared paper, 2026 · strength 0.28
  25. Masafumi Ikeda · 6 shared papers, 2013–2019 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.